Valion Bio, Inc. - Common Stock, par value $0.0001 per share (TIVC)
CUSIP: 888705308
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 2,789,768
- Total 13F shares
- 81,915
- Share change
- -12,668
- Total reported value
- $118,778
- Price per share
- $1.45
- Number of holders
- 7
- Value change
- -$96,033
- Number of buys
- 6
- Number of sells
- 1
Quarterly Holders Quick Answers
What is CUSIP 888705308?
CUSIP 888705308 identifies TIVC - Valion Bio, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 888705308:
Top shareholders of TIVC - Valion Bio, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Marc Lasry |
13F
|
Individual |
3.6%
|
101,638
|
$293,734 | — | 30 Sep 2025 | |
| DRW Securities, LLC |
13F
|
Company |
1.9%
|
53,935
|
$155,872 | — | 30 Sep 2025 | |
| Marex Group plc |
13F
|
Company |
1.4%
|
38,393
|
$110,956 | — | 30 Sep 2025 | |
| Jennifer Ernst |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
132,397
mixed-class rows
|
$61,132 | — | 18 Dec 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.05%
|
1,430
|
$4,133 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
801
|
$2,315 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
16
|
$46 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
8
|
$23 | — | 30 Sep 2025 | |
| John Claude |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,196,000
|
— | — | 10 Nov 2021 | |
| Blake Gurfein |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
235,000
mixed-class rows
|
— | — | 18 Dec 2024 | |
| Veronica Cai |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
117,880
|
— | — | 01 Apr 2022 | |
| Briana Benz |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
112,500
|
— | — | 10 Nov 2021 | |
| Ryan Sabia |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
100,000
|
— | — | 08 May 2023 | |
| Dean Zikria |
3/4/5
|
Director |
—
mixed-class rows
|
10,500
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Kimberly Ann Bambach |
3/4/5
|
Interim CFO |
—
class O/S missing
|
7,500
|
— | — | 01 Oct 2024 | |
| Karen Drexler |
3/4/5
|
Director |
—
class O/S missing
|
3,000
|
— | — | 30 Sep 2024 |
Institutional Holders of Valion Bio, Inc. - Common Stock, par value $0.0001 per share (TIVC) as of Q4 2025
As of 31 Dec 2025,
Valion Bio, Inc. - Common Stock, par value $0.0001 per share (TIVC) was held by
7 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
81,915 shares.
The largest 7 holders included
Marex Group plc, UBS Group AG, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITIGROUP INC, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., and BANK OF AMERICA CORP /DE/.
This page lists
7
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
7
Q4 2025 holders
7
Holder diff
0
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.